



Statistical Methods for Modeling Time-Updated Exposures in Cohort Studies of Chronic Kidney Disease

Dawei Xie,^{*†} Wei Yang,^{*†} Christopher Jepson,[†] Jason Roy,^{*†} Jesse Y. Hsu,^{*†} Haochang Shou,^{*†} Amanda H. Anderson,^{*†} J. Richard Landis,^{*†} and Harold I. Feldman^{*†} on behalf of the Chronic Renal Insufficiency Cohort (CRIC) Study Investigators

Abstract

When estimating the effect of an exposure on a time-to-event type of outcome, one can focus on the baseline exposure or the time-updated exposures. Cox regression models can be used in both situations. When time-dependent confounding exists, the Cox model with time-updated covariates may produce biased effect estimates. Marginal structural models, estimated through inverse-probability weighting, were developed to appropriately adjust for time-dependent confounding. We review the concept of time-dependent confounding and illustrate the process of inverse-probability weighting. We fit a marginal structural model to estimate the effect of time-updated systolic BP on the time to renal events such as ESRD in the Chronic Renal Insufficiency Cohort. We compare the Cox regression model and the marginal structural model on several attributes (effects estimated, result interpretation, and assumptions) and give recommendations for when to use each method.

Clin J Am Soc Nephrol 12: 1892–1899, 2017. doi: <https://doi.org/10.2215/CJN.00650117>

^{*}Department of Biostatistics, Epidemiology and Informatics, and [†]Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Introduction

In cohort studies an exposure often changes over time. Such an exposure is called “time-dependent,” “time-varying,” or “time-updated.” It is often of interest to study the effect of a time-updated exposure on an event-type outcome. When confounders also change over time, there is a circular relationship between the exposure and confounder, with the confounder affecting the exposure and the exposure affecting subsequent values of the confounder, a situation referred to as time-dependent confounding. An example is illustrated in Figure 1, in which the effect of systolic BP (SBP) (the exposure) on ESRD is confounded by eGFR in a time-dependent fashion.

When time-dependent confounding exists, the estimated effects of the time-updated exposure on outcome in a Cox regression model with time-updated covariates may be biased. This is because the regression model controls for variables that are, in part, affected by earlier exposures. Thus, some of the effect is being controlled for, rather than estimated. Marginal structural models (MSMs) are designed to correctly estimate the effect of a time-updated exposure in the presence of time-dependent confounding; this is accomplished through inverse-probability weighting (IPW). This article will review the Cox regression model and the MSM model with the focus on the latter. We will compare the Cox regression model and the MSM model on several aspects, such as the effects these models are estimating, the interpretation of the results, and the key assumptions. We will also provide recommendations regarding situations in which one would use MSM versus Cox models.

Motivating Example: Time-Updated SBP and the Progression of CKD

The Chronic Renal Insufficiency Cohort (CRIC) study is a multicenter cohort study of individuals with CKD.

The study enrolled 3939 individuals from seven clinical centers in the United States between 2003 and 2008. The details of the study design and participant characteristics and findings are reported elsewhere (1–3).

In the CRIC study, one of the main outcomes of interest is ESRD, for which hypertension is a common comorbidity—80% of the participants were hypertensive at baseline. To estimate the effects of SBP on ESRD, CRIC study investigators published a paper (4) in which both Cox regression model and the MSM approach were used. The paper also provided details of the rationale behind the research question.

Participants were followed up through annual clinic visits at which SBPs were measured. Other annually updated variables included eGFR, urine protein-to-creatinine ratio, diabetes mellitus, hypertension awareness, history of cardiovascular disease, body mass index, number of antihypertensive medication classes received, and angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker use. The detailed definition of these variables can be found in the paper mentioned above (4).

Cox Regression Model and the MSM

The Cox regression model can be used to study the association between baseline or time-updated SBP and ESRD. The setup for the Cox regression model makes it easy to handle time-updated covariates. When baseline and time-updated exposures are included, Cox regression produces different estimates for their effects. When including only baseline exposure in the model, Cox regression is estimating the “long-term” effect. “Long term” means that we are estimating the effect of baseline exposure using all of the events across the whole length of follow-up. By contrast, the effect of time-updated exposure on the

Correspondence:

Dr. Dawei Xie, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, 617 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104. Email: dxie@mail.med.upenn.edu




Figure 1. | Time Dependent Confounding illustrated. (A) Time-dependent confounding is absent. (B) Time-dependent confounding is present. The difference between (A) and (B) is that there is an additional arrow from SBP₀ to eGFR₁ in (B). It means that SBP₀ is also associated with eGFR₁. In other words, eGFR₁ is on the causal pathway between SBP₀ and ESRD₂. This kind of confounding is called time-dependent confounding. For simplicity, we omitted the arrow from eGFR₀ to eGFR₁ and from eGFR₀ to SBP₁. eGFR₀, eGFR at time 0; eGFR₁, eGFR at time 1; ESRD₂, ESRD status at time 2; SBP₀, SBP at time 0; SBP₁, SBP at time 1.

event estimated by the Cox model with time-updated exposure is “short-term,” where “short term” is defined as the interval between successive updates of exposures. For example, in the CRIC study, in which SBP was updated annually, the short term would be about 1 year. The estimation of the short-term effect is accomplished as follows: a separate Cox regression model is run for each interval, the beginning of which is defined as the point in time when the exposure was updated. The final estimate of the hazard ratio (HR) generated by the model is a weighted average of the individual HRs for each interval. Interested readers can refer to Dekker *et al.* (5) for more discussion on long- and short-term effects and figures to illustrate the difference between them.

The MSM differs from the Cox regression model in at least two ways. First, instead of modeling separately the effects of baseline and time-updated exposures on outcome, it models the effect of the entire history of exposure. For example, if we measure SBP at two time points (*e.g.*, at baseline and year 1 visits) and SBP is categorized into two levels (low/high), then the history of SBP can be summarized by the four possible combinations defining four groups of patients: group 1: SBP=low at both time points; group 2: SBP=low at baseline and high at year 1; group 3: SBP=high at baseline and low at year 1; and group 4: SBP=high at both time points. The MSM is able to estimate HRs comparing any two of these groups. For example, if we treat group 1 as the reference, we can obtain three HRs comparing groups 2, 3, and 4 to group 1.

Second, the MSM correctly estimates the effects when there is time-dependent confounding. To explain how the effects estimated by the MSM differ from those estimated by the Cox regression model, we will first discuss confounding and time-dependent confounding.

Confounding and IPW

In observational studies, exposures are not randomized and there is typically confounding. We can account for the confounding by adjusting for or stratifying by those measured

confounders. Alternatively, we can use the IPW approach to adjust for those confounders.

The IPW approach weights each subject by the inverse of the probability of that subject’s *observed* exposure. To understand this, consider an exposure that can be expressed as a yes/no variable (*e.g.*, 1=hypertension, 0=no hypertension). The IPW approach starts by estimating the probability of having an exposure value of what is observed. The inverse of the probability is the weight assigned to each subject. For example, if a subject’s observed exposure X is 1, the weight given to the subject will be the inverse of the probability that X=1, on the basis of the subject’s confounder measurements. Similarly, if a subject’s observed exposure X is 0, the weight will be the inverse of the probability that X=0, on the basis of the subject’s confounder measurements.

Illustration of IPW When There Is Only One Confounder and One Time Point

To illustrate the IPW approach, we give an example with hypothetical data. In this example, hypertension (two levels: Yes/No) is the main exposure, ESRD (two levels: Yes/No) the outcome, and eGFR level (two levels: High/Low) the only confounder. Table 1 shows a hypothetical distribution of participants with and without ESRD, stratified by both eGFR and hypertension; Tables 2–4 depict the same data, but stratified by only one of the variables.

From these tables, we can see that: eGFR is a confounder, as it is associated with the exposure (Table 3) and the outcome (Table 4); hypertension is not associated with ESRD when we stratify by eGFR (Table 1); and hypertension seems to be associated with ESRD if we do not control for the confounding of eGFR (Table 2).

Now we will show how to use the IPW approach to adjust for confounding. Table 3 gives the probability that hypertension=Yes or No within each stratum of eGFR. Note that these are conditional probabilities, as they are conditional on the value of eGFR. IPW is then defined as the inverse of these conditional probabilities (Table 5).

We can then apply these weights to each subject according to their hypertension and eGFR values. The results are shown in Tables 6 and 7, which correspond to the upper and lower

Table 1. Hypothetic distribution for hypertension and ESRD stratified by eGFR level

Confounder	Exposure: Hypertension (n, row %)	Outcome: ESRD		Total
		Yes	No	
eGFR=High	Yes	250	1000	1250
		20%	80%	
	No	750	3000	3750
		20%	80%	
Total		1000	4000	5000
		20%	80%	
eGFR=Low	Yes	1250	1250	2500
		50%	50%	
	No	1250	1250	2500
		50%	50%	
Total		2500	2500	5000
		50%	50%	

Table 2. Hypothetic distribution for hypertension and ESRD without stratifying by eGFR level

Exposure: Hypertension	Outcome: ESRD		Total
	Yes	No	
Yes	1500 40%	2250 60%	3750
No	2000 32%	4250 68%	6250
Total	3500 35%	6500 65%	10,000

halves of Table 1 respectively—the number of subjects in each cell of Table 1 is multiplied by the weight assigned to the subjects in that cell. We can then collapse Tables 6 and 7 to get Table 8, which shows the marginal association between hypertension and ESRD after weighting. We can see that the IPW approach concludes that there is no association between hypertension and ESRD. This is consistent with the stratified results shown in Table 1.

Stabilized and Unstabilized Weights

We can stabilize (or equivalently, reduce) the variance in the weights derived above (called the unstabilized weights) by multiplying the unstabilized weight by the probability of observed exposure without conditioning on the confounders. Specifically, the stabilized weight is the ratio of the unconditional probability (the numerator) to the conditional probability (the denominator).

We illustrate the calculation of stabilized weights by going back to the example in Tables 1–4. The bottom row of Table 3 gives the unconditional probabilities of exposure, which are $P(\text{hypertension}=\text{yes})=37.5\%$ and $P(\text{hypertension}=\text{No})=62.5\%$. Table 9 shows how to calculate the stabilized weights. We can see that the stabilized weights are distributed around 1 and have a smaller variance than the unstabilized weights.

Time-Dependent Confounding

In the example given above, both the exposure and the confounder were measured at only one time point. When both exposure and confounders are time-updated, situations can arise in which we have not only the confounders affecting exposure, but also exposure affecting later confounders. In other words, the later confounders are in the

Table 3. Hypothetic distribution for eGFR and hypertension

Confounder: eGFR	Exposure: Hypertension		Total
	Yes	No	
High	1250 25%	3750 75%	5000
Low	2500 50%	2500 50%	5000
Total	3750 37.5%	6250 62.5%	10,000

Table 4. Hypothetic distribution for eGFR and ESRD

Confounder: eGFR	Outcome: ESRD		Total
	Yes	No	
High	1000 20%	4000 80%	5000
Low	2500 50%	2500 50%	5000
Total	3500 35%	6500 65%	10,000

causal pathway between the previous exposure and the outcome. When this happens, we say there is time-dependent confounding.

In Figure 1, we use the data from the motivating example to illustrate the concept of time-dependent confounding. Suppose here that SBP is the main exposure, eGFR is a confounder, and ESRD is the outcome. SBP at baseline (SBP_0) is associated with ESRD at time 2 ($ESRD_2$). Because eGFR at baseline ($eGFR_0$) is a confounder, we see two arrows from it indicating that $eGFR_0$ is associated with SBP_0 and $ESRD_2$. At time 1, we have the same situation— $eGFR_1$ is a confounder, which means that it is associated with SBP_1 and $ESRD_2$. The difference between Figure 1, (A) and (B) is that there is an additional arrow from SBP_0 to $eGFR_1$ in Figure 1B. It means that SBP_0 is also associated with $eGFR_1$. In other words, $eGFR_1$ is on the causal pathway between SBP_0 and $ESRD_2$. This kind of confounding is called time-dependent confounding. When there is time-dependent confounding, and we are interested in the causal effect of time-updated exposure on a time-to-event outcome, Robins *et al.* (6) showed that the Cox regression model with time-updated covariates may be biased.

MSMs

When time-dependent confounding exists, MSMs can be used to estimate the causal effect of a time-updated exposure on a time-to-event outcome. This model is also called the marginal structural Cox proportional hazards model (6). As this name implies, the MSM is essentially a Cox model. The main difference between MSM and the Cox regression model described earlier is that MSM is a weighted model in which time-dependent confounding is controlled *via* IPW.

IPW When There Are Multiple Confounders and One Time Point

In our earlier illustration of the derivation of IPWs, there was only a single binary confounder, allowing us to derive weights easily from simple crosstabulations. When there are many confounders, IPWs can be estimated *via* regression models. Specifically, logistic or multinomial logistic regression can be used when the exposure is binary or multilevel. When the exposure is a continuous variable, there are some difficulties in deriving the IPWs (5–7). To avoid these difficulties, one can categorize the continuous exposure. In our motivating example, we divided SBP into four categories and used multinomial logistic regression for the weight estimation.

Table 5. Illustration of definition of inverse-probability weight

Confounder: eGFR	Exposure: Hypertension	
	Yes	No
High	P(hypertension=Yes when eGFR=High)=25% IPW=1/25%=4	P(hypertension=No when eGFR=High)=75% IPW=1/75%=4/3
Low	P(hypertension=Yes when eGFR=Low)=50% IPW=1/50%=2	P(hypertension=No when eGFR=Low)=50% IPW=1/50%=2

P, probability of; IPW, inverse probability weight.

IPW When There Are Multiple Time Points

When exposures and confounders are measured at multiple time points, IPWs are calculated at each time point, and are the inverse of the probability of observed exposure history given the confounder history. To understand this, let us extend our previous illustration such that the exposure (hypertension) and confounder (eGFR) are measured at two time points, and consider a subject with values of 1 on hypertension at both points. The IPW at time 1 for this subject is derived in the same fashion as previously described. At time 2, however, the IPW is on the basis of the probability that the subject has a value of 1 on hypertension at both time 1 and time 2 (the subject’s observed exposure history), given their values on eGFR at time 1 and time 2 (the observed confounder history). This is equivalent to the product of two probabilities: (1) the probability that the subject has a value of 1 on hypertension at time 1, given their value on eGFR at time 1; and (2) the probability that the subject has a value of 1 on hypertension at time 2, given their values on eGFR at time 1 and 2 and their value on hypertension at time 1. These conditional probability terms can be estimated *via* appropriate regression models.

Inverse Probability Censoring Weight and Inverse Probability Treatment Weight

When we are interested in a time-to-event outcome, typically there is censoring because of study dropout or reaching the administrative end of follow-up. Censoring can also be handled using IPW. Similar to the IPW to adjust for confounders (to avoid confusion, we now call that weight the “inverse probability treatment weight [IPTW]”), the weight adjusting for censoring (called the “inverse probability

censoring weight [IPCW]”) also has unstabilized and stabilized versions.

The unstabilized IPCW is defined as the probability of staying in the study up to the current time point given the past exposure and confounder history. Similar to IPTW, we can decompose this probability into the product of conditional probability terms.

To obtain the stabilized IPCW, we multiply the unstabilized IPCW by the probability of staying in the study up to the current time point given the past exposure history. Therefore, the stabilized IPCW is also defined as a ratio. Both the numerator and the denominator are the product of a series of conditional probability terms. The numerator conditions on exposure history, whereas the denominator conditions on exposure history and confounder history. These conditional probability terms can also be estimated *via* appropriate regression models. Table 10 illustrates the definitions of stabilized IPTW and IPCW at multiple time points. (Table 10 also shows the unstabilized versions of these weights, because, as indicated above, they are the denominators of the stabilized versions.) The final weight at each time point is then defined as IPTW×IPCW. Weight truncation (6) can be considered when we finalize the weights.

Discrete Failure Time Model

As illustrated previously, IPW may vary over time for each subject if we have multiple time points. No standard software for Cox regression can handle time-updated weights. One solution is to use the discrete failure time model to replace the Cox model; this is the typical practice for MSMs. Note that although the MSM is also called the marginal structural Cox proportional hazards model, in

Table 6. Hypothetic distribution for hypertension and ESRD when eGFR level is high after applying inverse-probability weighting

Confounder: eGFR=High	Exposure: Hypertension (n, row %)	Outcome: ESRD		Total
		Yes	No	
	Yes	250×4=1000 20%	1000×4=4000 80%	5000
	No	750×(4/3)=1000 20%	3000×(4/3)=4000 80%	5000
	Total	2000 20%	8000 80%	10,000

Table 7. Hypothetic distribution for hypertension and ESRD when eGFR level is low after applying inverse-probability weighting

Confounder: eGFR=Low	Exposure: Hypertension (n, row %)	Outcome: ESRD		Total
		Yes	No	
	Yes	1250×2=2500 50%	1250×2=2500 50%	5000
	No	1250×2=2500 50%	1250×2=2500 50%	5000
	Total	5000 50%	5000 50%	10,000

practice the Cox proportional hazards model is often replaced by the discrete failure time model which can produce equivalent estimates.

The discrete failure time model is actually a pooled logistic regression model. The first step is to divide time into small intervals. Within each small interval, we can define the values for exposure, confounders, and outcome for each subject. The time-to-event outcome is defined as a binary outcome within each interval. That is, if a subject experiences the outcome within a given interval, that subject's outcome for that interval is defined as "Yes" and otherwise "No." Each subject contributes either one record, or multiple records, to the analysis, depending on the number of intervals during which the subject is followed up. We then "pool" all of the records from all subjects together to fit a logistic regression model. A generalized estimating equation procedure (for example, option "repeated" in PROC GENMOD in SAS) can then be used to account for the within-subject correlation.

If we fit a logistic regression for the discrete failure time model, the odds ratios from the logistic regression model approximate the HRs from the Cox regression model more closely as the intervals used become shorter and shorter.

The discrete failure time model can naturally incorporate time-updated exposures and confounders. Time-updated weights can also be incorporated easily (*e.g.*, using option SCWGT in PROC GENMOD in SAS).

Assumptions for Cox Regression Models and MSMs

Assumptions for Cox Regression Models

For Cox regression models, an implicit assumption is noninformative censoring. In other words, the design of the

underlying study must ensure that the mechanisms giving rise to censoring of individual subjects are not related to the probability of an outcome event occurring.

For Cox regression models for baseline exposures, the second often-made assumption is the proportional hazards assumption. It means that the HR is assumed to remain unchanged over the whole length of follow-up. The Cox regression models with time-updated exposure often assume the same assumptions.

Assumptions for MSMs

MSMs share the same assumptions with the Cox regression. In addition, MSMs make additional assumptions including exchangeability, positivity, and correct specification of the weight models. Note that MSMs can explicitly handle noninformative censoring through IPCW.

The exchangeability assumption is equivalent to assuming that there is no unmeasured confounding in observational studies. By definition, this assumption is not easy to test explicitly (*i.e.*, we cannot assess the effect of a variable we have not measured); therefore, we typically just assume that it holds.

The positivity assumption was checked in our motivating example. Specific to the example, it requires that there are observed individuals in all four SBP categories for any stratum corresponding to a particular combination of the baseline covariates. We evaluated the assumption on the basis of the large sample size and the distribution of the final weights.

For the correct specification of weight model, Cole and Hernan (7) discussed strategies in model building in more detail. In summary, the goal of model building is to achieve a balance between bias and variance. If we control for too many confounders, it might lead to violation of the positivity assumption and the variance in the final estimates might increase. If we control for too few confounders, then the estimates will be biased. Cole and Hernan (7) fitted six different weight models. For each weight model, they showed the estimate and the variance in the final model. They selected their weight model on the basis of the bias and the variance of the final estimates. Detailed discussions can be found in other papers (8).

Table 8. Hypothetic distribution for hypertension and ESRD after applying inverse-probability weighting

Exposure: Hypertension	Outcome: ESRD		Total
	Yes	No	
Yes	3500 35%	6500 65%	10,000
No	3500 35%	6500 65%	10,000
Total	7000 35%	13,000 65%	20,000

Implementation of Cox Regression Model and MSM Approach Using CRIC Data

The details of implementing the Cox regression model and the MSM model in the motivating example are given in

Table 9. Illustration of definition of stabilized inverse-probability weighting

Confounder: eGFR	Exposure: Hypertension	
	Yes	No
High	P(hypertension=Yes when eGFR=High)=25% Unstabilized IPW=1/25%=4 P(hypertension=Yes)=37.5% Stabilized IPW=4×37.5%=1.5	P(hypertension=No when eGFR=High)=75% Unstabilized IPW=1/75%=4/3 P(hypertension=No)=62.5% Stabilized IPW=(4/3)×62.5%=0.83
Low	P(hypertension=Yes when eGFR=Low)=50% Unstabilized IPW=1/50%=2 P(hypertension=Yes)=37.5% Stabilized IPW=2×37.5%=0.75	P(hypertension=No when eGFR=Low)=50% Unstabilized IPW=1/50%=2 P(hypertension=No)=62.5% Stabilized IPW=2×62.5%=1.25

P, probability of; IPW, inverse probability weight.

the Supplemental Appendix. We choose several key points to mention here.

First, we categorized the continuous exposure (SBP) into four categories (<120, 120–129, 130–139, and ≥140 mmHg) and used multinomial logistic regression models to estimate the treatment weights. These cutoff points were chosen because of clinical relevance.

Second, for the models of numerators for the IPTW and IPCW, we chose to include some baseline covariates to further reduce the variability of the weights. As a result, the causal effect estimated was not in fact unconditional (marginal), but, rather, conditional on the included covariates (7). This affects the interpretation of the model estimates from the MSM.

Third, ideally we want to draw causal conclusions for each scenario of the exposure history. In our previous illustration, we had two time points, at each of which SBP could take one of two values, high and low. It would be ideal if we can estimate three HRs from the MSM, comparing the risk of event for groups 2, 3, and 4 to the reference group (group 1). This kind of MSM, in which the number of parameters is the number of unique exposure history scenarios minus 1, is called the saturated MSM.

If the exposure is a categorical variable with *k* levels and we have *m* time points, then there are *k^m* possible exposure scenarios. In our motivating example, the exposure had four levels and there were eight time points, which means there are 4⁸=65,536 scenarios for exposure history. Needless to say, we did not have enough observations to estimate 65,535 parameters.

When the saturated MSM is not possible, it is important to summarize the exposure history. For a binary exposure, the summary could be the exposure level at the last time point (9) or the average exposure over the follow-up period. A categoric exposure can be represented by several dummy variables. The summary could also be several variables, *e.g.*, the average of those dummy variables. In our motivating example, we adopted this summarizing approach for a categoric exposure.

Analyses of the CRIC Data in the Motivating Example

For the data used by Anderson *et al.* (4), the median (25th, 75th percentiles) duration of follow-up was 5.7 (4.6, 6.7) years. The within-participant mean SBP over time ranged from 74 to 218 mmHg (mean [SD]: 128.6 [19.1]). A total of 33.1%, 19.2%, and 10.6% of the participants, respectively, had SBP at or above 120, 130, and 140 mmHg at all of their study visits.

Table 10. Illustration of stabilized IPTW and IPCW definitions with multiple time points

Stabilized Weights		Time 1	Time 2	Time 3
IPTW	Numerator ^a	$P(X_1=a_1)$	$P(X_2=a_2 X_1=a_1) \times P(X_1=a_1)$	$P(X_3=a_3 X_1=a_1, X_2=a_2) \times P(X_2=a_2 X_1=a_1) \times P(X_1=a_1)$
	Denominator ^a	$P(X_1=a_1 \bar{L}_1)$	$P(X_2=a_2 X_1=a_1, \bar{L}_2) \times P(X_1=a_1 \bar{L}_1)$	$P(X_3=a_3 X_1=a_1, X_2=a_2, \bar{L}_3) \times P(X_2=a_2 X_1=a_1, \bar{L}_2) \times P(X_1=a_1 \bar{L}_1)$
IPCW	Numerator ^a	$P(C_1=0 \bar{A}_1)$	$P(C_2=0 C_1=0, \bar{A}_2) \times P(C_1=0 \bar{A}_1)$	$P(C_3=0 C_1=0, C_2=0, \bar{A}_3) \times P(C_2=0 C_1=0, \bar{A}_2) \times P(C_1=0 \bar{A}_1)$
	Denominator ^a	$P(C_1=0 \bar{A}_1, \bar{L}_1)$	$P(C_2=0 C_1=0, \bar{A}_2, \bar{L}_2) \times P(C_1=0 \bar{A}_1, \bar{L}_1)$	$P(C_3=0 C_1=0, C_2=0, \bar{A}_3, \bar{L}_3) \times P(C_2=0 C_1=0, \bar{A}_2, \bar{L}_2) \times P(C_1=0 \bar{A}_1, \bar{L}_1)$

X1, X2, and X3 are the exposure; *a*₁, *a*₂, and *a*₃ are the values of exposure; and the confounder history (*i.e.*, confounder values since baseline to this time point) is \bar{L}_1 , \bar{L}_2 , and \bar{L}_3 at time points 1, 2, and 3. *C*₁, *C*₂, and *C*₃ are the censoring indicators at time points 1, 2, and 3 for one subject. They are defined as 1 if right-censored by that time point, and 0 otherwise. \bar{A}_1 , \bar{A}_2 , and \bar{A}_3 are the exposure history at time points 1, 2, and 3. IPTW, inverse probability treatment weight; P, probability of; IPCW, inverse probability censoring weight.

^aWe can adjust for baseline covariates *L*₀ in all models.

Table 11. Multivariable associations of baseline and time-updated systolic BP with renal endpoints in the Chronic Renal Insufficiency Cohort Study

Renal Endpoint: ESRD Categoric SBP (Reference: SBP <120)	Models of Baseline SBP Hazard Ratio (95% CI)	Models of Time-Updated SBP ^a Hazard Ratio (95% CI)
SBP 120–129	1.06 (0.82 to 1.37)	0.92 (0.54 to 1.57)
SBP 130–139	1.46 (1.14 to 1.89)	2.25 (1.41 to 3.60)
SBP ≥140	1.48 (1.18 to 1.85)	3.30 (2.21 to 4.94)

All models are stratified by clinical center, and adjusted for age, sex, race/ethnicity, education, hypertension awareness, history of cardiovascular disease, body mass index, number of antihypertensive medication classes, angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker use, diabetes status, eGFR, and urine protein-to-creatinine ratio. SBP, systolic BP; 95% CI, 95% confidence interval.

^aUsing MSMs with adjustment for all covariates listed above and study time (all time-updated with the exception of sex, race/ethnicity, education level, and hypertension awareness); HR estimates depicted using MSMs and using categorical SBP reflect the risk of the renal endpoint for selected scenarios in which SBP at all study visits consistently fell into that BP category.

Over follow-up, 699 participants developed ESRD, corresponding to an event rate of 38.0 per 1000 person-years.

For the analysis, we fitted Cox regression models with baseline SBP and marginal structural Cox regression models. Note that the HRs from the two models had different interpretations. From the Cox regression model with baseline SBP, after multivariable adjustment, participants with baseline SBP >130 mmHg had significantly increased risk for ESRD across the whole length of follow-up compared with those whose baseline SBP was <120 mmHg. The results from the Cox regression model with time-updated covariates were not reported because that is not the appropriate approach. From the MSMs, we chose to adjust for baseline covariates which led to further reduction in the variability of the weights. The risk of ESRD for participants who had a time-updated SBP between 130 and 139 or ≥140 mmHg at all time points was 2.25–3.30 times the risk for those with a time-updated SBP always <120 mmHg (reference group; Table 11) given the adjusted baseline covariates.

When to Use Each Approach?

When one is interested in the “long-term” effect of the baseline exposure, or equivalently, wants to associate the

baseline exposure with the outcomes occurring throughout the follow-up period, one can use the Cox model with baseline exposure (Table 12), adjusting for baseline covariates only.

When one is interested in studying the effects of time-updated exposure on an outcome, the MSM approach is the right choice with proper adjustment of time-dependent confounding. However, if the interest is only the short-term effect of the most recent exposure on an outcome, then the Cox regression model for time-updated exposure adjusting for time-updated covariates is a reasonable approach to consider.

Discussion

In this article, we compared several approaches for analyzing time-to-event outcomes. The approaches include the Cox regression model with baseline exposure, the Cox regression model with time-updated exposure, and MSM.

We discussed the situations in which each approach is appropriate. Note that the questions that each approach can answer are different. In other words, the three approaches are estimating different effects. It is possible to compare the “long-term” and “short-term” effects from the Cox regression models with baseline exposure and those with time-updated exposure. However, the effects of time-updated exposure from the MSM

Table 12. Comparisons among the approaches

Variable	Cox Regression with Baseline Exposure	Cox Regression with Time-Varying Exposure	MSM
Effects estimated	“Long-term” effects	“Short-term” effects	Effects of the whole exposure history
Correctly estimate effects of time-updated exposure when time-dependent confounding is present	N/A	No	Yes
Assumptions	Noninformative censoring, proportional hazard	Noninformative censoring, proportional hazard	Noninformative censoring, proportional hazard, exchangeability, positivity, and correct specification of weight models
Programming	Easy	Easy	Tedious

MSM, marginal structural model; N/A, not applicable.

are not so comparable to the Cox regression estimates. The comparison on the scale of the effects is not meaningful and the direction of the effects might be the only aspect that can be compared.

There are several limitations for MSMs. For example, MSMs cannot examine effect modification by variables measured after baseline. In addition, MSMs cannot be used when the positivity assumption is violated. Other methods, *e.g.*, structural nested models (10,11), can be used but are more difficult to implement in practice.

There are many cohort studies collecting data on patients with CKD, and many of the exposures of interest are time-updated. Cox regression models with baseline or updated exposure are easy to implement in standard statistical packages and thus represent a convenient choice. However, the issue of time-dependent confounding must be considered when estimating the effect of whole exposure history.

MSM can estimate the effects of the whole history of exposure and can properly handle time-dependent confounding through IPW. Therefore, it should be considered in the analysis of CKD cohort studies. MSM can also be used to analyze health record data where people are seen at variable intervals. The implementation is the same as in the cohort studies in principle.

There are some difficulties in implementing MSM. First, it takes some time for the clinical audience to understand the approach and the interpretation of the estimates. Second, the programming of the MSMs can be very tedious (Table 12). To overcome these difficulties, in recent years the National Institute of Diabetes and Digestive and Kidney Diseases has sponsored the CRIC study to provide an annual research workshop (12) to the wider community of CKD researchers, and the MSM was one of the topics covered in those workshops. We hope that the CKD research community can benefit from these efforts to have a better understanding of these approaches and use appropriate methods for the analysis of CKD studies.

Acknowledgements

Funding for the Chronic Renal Insufficiency Cohort Study was obtained under a cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, and U01DK060902). Additional funding was provided by U01DK85649 (CKD Biocon).

Disclosures

None.

References

1. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL, He J, Hostetter T, Hsu CY, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER 3rd, Muntner P, Ojo AO, Rahman M, Townsend RR, Wright JT; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and methods. *J Am Soc Nephrol* 14 [Suppl 2]: S148–S153, 2003
2. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J, Fink JC, Fischer MJ, Gadegbeku C, Hamm LL, Kusek JW, Landis JR, Narva A, Robinson N, Teal V, Feldman HI; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Chronic Renal Insufficiency Cohort (CRIC) Study: Baseline characteristics and associations with kidney function. *Clin J Am Soc Nephrol* 4: 1302–1311, 2009
3. Denker M, Boyle S, Anderson AH, Appel LJ, Chen J, Fink JC, Flack J, Go AS, Horwitz E, Hsu CY, Kusek JW, Lash JP, Navaneethan S, Ojo AO, Rahman M, Steigerwalt SP, Townsend RR, Feldman HI; Chronic Renal Insufficiency Cohort Study Investigators: Chronic Renal Insufficiency Cohort Study (CRIC): Overview and summary of selected findings. *Clin J Am Soc Nephrol* 10: 2073–2083, 2015
4. Anderson AH, Yang W, Townsend RR, Pan Q, Chertow GM, Kusek JW, Charleston J, He J, Kallem R, Lash JP, Miller 3rd ER, Rahman M, Steigerwalt S, Weir M, Wright Jr. JT, Feldman HI; Chronic Renal Insufficiency Cohort Study Investigators: Time-updated systolic blood pressure and the progression of chronic kidney disease: A cohort study. *Ann Intern Med* 162: 258–265, 2015
5. Dekker FW, de Zeeuw D, van Dijk PC, Zoccali C, Jager KJ: Survival analysis: Time-dependent effects and time-varying risk factors. *Kidney Int* 74: 994–997, 2008
6. Robins J: Marginal structural models versus structural nested models as tools for causal inference. In: *Statistical Models in Epidemiology: The Environment and Clinical Trials*, edited by Halloran E, Berry D, New York, Springer-Verlag, 1999, pp 95–134
7. Cole SR, Hernán MA: Constructing inverse probability weights for marginal structural models. *Am J Epidemiol* 168: 656–664, 2008
8. Cole SR, Frangakis CE: The consistency statement in causal inference: A definition or an assumption? *Epidemiology* 20: 3–5, 2009
9. Hernán MÁ, Brumback B, Robins JM: Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. *Epidemiology* 11: 561–570, 2000
10. Robins J, Tsiatis AA: Semiparametric estimation of an accelerated failure time model with time-dependent covariates. *Biometrika* 79: 311–319, 1992
11. Vansteelandt S, Joffe M: Structural nested models and G-estimation: The partially realized promise. *Stat Sci* 29: 707–731, 2014
12. University of Pennsylvania: CRIC Study Research Workshop, 2017. Available at: <http://www.med.upenn.edu/cric/>. Accessed May 22, 2017

Published online ahead of print. Publication date available at www.cjasn.org.

This article contains supplemental material online at <http://www.cjasn.org/lookup/suppl/doi:10.2215/CJN.00650117/-/DCSupplemental>.

Supplemental Material

Appendix: Implementation of marginal structural model in the motivating example using CRIC data

This appendix will provide more details on the implementation of the MSM in the motivating example. Recall that the time to ESRD was the outcome and SBP the exposure. The confounders include variables such as eGFR, PCRs, diabetes mellitus, hypertension awareness, history of CVD, BMI, number of antihypertensive medication classes received, and ACEI/ARB use. By design, the exposure and confounders were updated annually. The date of ESRD and the date of censoring were known.

The implementation of MSM consisted of these steps: data preparation for discrete failure time model, deriving the weights, and setting up the marginal structural model.

Data preparation for discrete failure time model

During this step, we needed to answer these questions: 1. How to divide the whole length of the follow-up time into intervals? In other words, how long should each interval be? 2. How to define exposure, confounders, and outcome in each interval? 3. How to deal with missing data?

For the first question, the answer depends on how frequently the data is updated. Sometimes all data including exposure, confounders, and outcome are updated with the same frequency, say, daily⁵. In such a case, it is natural to define the interval according to this frequency. Please note that the decision regarding how to divide the follow-up time into intervals is only for the implementation of the discrete failure time model. It should not be used to decide the time updating schedule.

There could also be situations in which these variables are updated at different frequencies. In this case, different intervals can be tried in sensitivity analysis. In our motivating example, the exposure and confounders were updated annually while the outcome and censoring indicator were updated daily. We decided to divide the time into yearly intervals.

For the second question, it is not a problem if all variables were updated with the same frequency. For example, if all data were updated daily and there is only one value for each variable on each day, there is no choice to make. In our motivating example, however, the data were not updated at the same frequency. The length of the interval was one year while the outcome and censoring indicator were updated daily. Therefore, the outcome and the censoring indicator could change their values during an interval. Even for the exposure and confounders, values could change during an interval because some study participants came to an annual visit earlier or later than expected. In our motivating example, we used the set of exposure and confounders closest to the beginning of an interval in either direction. For the outcome and censoring indicator, we used the value at the end of an interval. In other words, if the censoring indicator was 0 (i.e., not censored) at the beginning of an interval and changed to 1 by the end of an interval, we defined the censoring indicator to be 1. The same procedure was followed for the outcome.

For the third question, missing values in exposure and confounders can be handled in various ways according to the situation. In our motivating example, missing SBPs were imputed using the last observation carried forward approach if the participants returned for a later study visit (84 out of 3,708, or 2% of participants). Participants with missing SBPs who never returned for a study visit during the remainder of the period under study were censored at the last observed

SBP. We also performed sensitivity analysis by censoring at the time of the last SBP whenever there was a missing SBP.

Deriving the weights

Again there are several questions to consider: 1. Which regression models to use for the weights? 2. Which covariates to include in the weight models? Any lag terms or other terms to consider in the weight models? Do we want to adjust for baseline covariates? 3. What is the distribution for the final weight? How to truncate the final weight?

For the first question, as discussed before, logistic or multinomial logistic regression models are commonly used for estimating the conditional probability terms for the numerators and denominators for IPTW and IPCW. In our motivating example, we chose to categorize the continuous exposure (SBP) into 4 categories (<120 , 120 to 129, 130 to 139, and ≥ 140 mm Hg) and use multinomial logistic regression models to estimate the weights.

For the second question, we need to decide confounders to be included in the denominator and numerator for the IPTW and IPCW models. For the denominator, from Table 3, we can see that the whole confounder history should be considered in the weight models. This means that we might need to include lag terms of the confounders in the models (lag terms are the values of the confounders from the previous data points). A natural question to ask next is how many lag terms to include for each confounder. If sample size is large enough for us to include all available lag terms, then we need to fit a separate model for each interval as there are different numbers of lag terms for each interval. When study participants have different lengths of follow-up and the sample sizes for the later intervals become small, it might not be feasible to include all available lag terms.

With fewer numbers of lag terms, it is possible to pool some intervals to fit one model. Some researchers have made a strong assumption that no lag terms for confounders need to be included in the models⁹. As discussed above, the whole history of exposure should be considered in the weight models; the decision of not including any lag terms needs to be justified.

In our motivating example, we included three lag terms for each time-updated confounder after trying different numbers of lag terms. We made this decision according to the significance of different lag terms in the weight model. We fit separate models for the first 3 intervals and pooled later intervals to fit another model. Since we have found that the relationship between eGFR and PCRs and the outcome (ESRD) in Cox regression models is non-linear, we included spline terms and the corresponding lag terms for these two confounders.

For the models of the numerator, from Table 3 we can see that exposure history should be included. We can also include other baseline covariates which can lead to further reduction in the variability of the weights. If baseline covariates are included here, then they need to be included in the models for the denominators as well as in the marginal structural model^{7,13}. In our motivating example, we decided to include three lag terms for the exposure and the baseline covariates in the models for the numerators and denominators.

Note that correct specification of the weight models is very important. One assumption of MSM is that the weight models are correct. If the weight models are not correct, then the estimates from the final model will not be consistent. The specification for the models of the numerators is relatively straightforward as we only need to consider exposure history and baseline covariates. It is not so important to select the baseline covariates correctly as long as the same baseline covariates are included in the denominator and the marginal structural models. For the denominator models,

the model building considerations should start as early as the study design. At that stage, researchers need to review literature and get expert opinions on what information to collect. During the study, we need to ensure that the important confounders are measured. In the model building stage, we include the important confounders in the models. Again we need to explore all the histories of both exposure and confounders in the model. More discussion is given in the summary section.

For the third question, we need to look at the distribution of the final weight which is IPTW \times IPCW at each time point. Weights that are very large or very small can lead to large variance in the final estimates. *Weight truncation* (or *weight trimming*) is commonly used to set large or small weights to threshold values. There are many papers discussing weight truncation. For example, in Cole and Hernan (2008)⁷, the recommendation was to truncate final weights at the 1st and the 99th percentile. Later, Xiao et al (2013) did simulation studies to show that no benefit was observed with truncation of weights at the left tail of the distribution. We found significant reduction in the variance and 95% coverage rates for the marginal structural model estimates if we truncated weights at the 99th or 99.5th percentile. Simulations also suggested that bias might increase with more truncation at the right tail of the weight distribution. In our motivating example, we tried different truncation thresholds and finally decided to truncate weights at value 10; only 8 weights were truncated using this method.

Setting up the marginal structural model

As discussed before, the association of an exposure with a time-to-event outcome can be estimated via a Cox regression model. This model is called the *marginal structural Cox regression model*. It is *marginal* because the model does not include time-updated confounders, as all

confounding effects are adjusted via IPWs. It is *structural* (that is, causal) because we can make causal inferences from it.

There are two questions to answer: 1. How to summarize the exposure history? 2. How to interpret model estimates with and without baseline covariates in the final model? For the first question, details can be found in the main text of the paper. For the second question, if we include baseline covariates in the weight models, we are assuming that the exposure or censoring is randomized within the levels of the included baseline covariates after weighting. There may still be confounding by the included baseline covariates. Therefore, we often adjust for them in the MSM. As a result, the causal effect estimated will not be unconditional (marginal), but rather, conditional on the included covariates⁷. This affects the interpretation of the model estimates from the MSM.

Other issues

Except for the steps outlined above, there are other questions such as whether there are effect modifications by baseline covariates, and how to do stratified analysis by baseline covariates. If we plan to test an interaction between a baseline covariate and exposure in the MSM, then the interaction has to be included in the weight models. We can then do stratified analysis using the weights derived from these models.

Analyses of the CRIC Data in the Motivating Example

In addition to the analysis reported in the main text, we also explored effect modification by an *a priori* selected set of baseline covariates and found that the strength of the association

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

between SBP and the outcome did not differ across the explored subgroups (results not shown here)⁴.

We checked one key assumption for MSM which is the so-called positivity assumption. Specific to this study, it requires that there are observed individuals in all four SBP categories for any stratum corresponding to a particular combination of the baseline covariates. We evaluated the assumption based on the large sample size and the distribution of the final weights. We also performed sensitivity analysis to evaluate the impact of the approaches of handling missing visits (See Technical appendix for Anderson et al⁴).